Vaccine against Covid-19: Pfizer-BioNTech believes that the efficacy against the Omicron variant is “improved with – franceinfo

Faced with concerns related to the new Omicron variant, the laboratories want to reassure. The vaccine against Covid-19 developed by the companies Pfizer and BioNTech is “always effective” against the Omicron variant after “three doses”, assured the two groups, Wednesday, December 8, in a joint press release (in English). However, the two companies wish to finalize a vaccine adapted to the variant. “by March”, they add.

According to studies carried out by the two companies, “Although two doses of the vaccine may still offer protection against severe disease caused by the Omicron strain, it is clear from this preliminary data that protection is improved with a third dose of our vaccine.”, notes Albert Bourla, President and CEO of Pfizer.

Pfizer and BioNTech will also “continue the development of a vaccine specific to the Omicron variant”, hoping “make it available by March in case an adaptation is necessary”.